

## **Stock exchange intimation to be released by CHL**

We hereby inform that Cadila Healthcare Ltd., has entered into an asset purchase agreement to sell its right, title and interest in ZYPITAMAG<sup>TM</sup> (Pitavastatin), along with applicable registrations and intangible assets relating to ZYPITAMAG for USA and Canada markets to Medicure Inc., a cardiovascular pharmaceutical company. Medicure had previously acquired U.S. marketing rights with a profit-sharing arrangement with Cadila. With this acquisition, Medicure retains all profits, with full control of marketing and pricing negotiation for USA and Canada markets.

Under terms of the agreement, Cadila will receive an upfront payment of U.S. \$5,000,000 and U.S. \$2,000,000 in deferred payments to be made over the next four years, contingent payments on achievement of sales milestones and royalties on net sales.

ZYPITAMAG<sup>TM</sup> is a HMG-CoA reductase inhibitor indicated for adult patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). ZYPITAMAG<sup>TM</sup> was approved in 2017 by the U.S. Food and Drug Administration for sale and marketing in the United States and was launched by Medicure in the second quarter of 2018 through a license agreement it had entered into with Cadila.

We request you to bring this news to the notice of the members of the exchange and the investors at large.